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SUMMARY
Despite progress in our comprehension of the
mechanisms regulating adipose tissue develop-
ment, the nature of the factors that functionally
characterize adipose precursors is still elusive.
Defining the early steps regulating adipocyte devel-
opment is needed for the generation of tools to
control adipose tissue size and function. Here, we
report the discovery of V-set and transmembrane
domain containing 2A (VSTM2A) as a protein
expressed and secreted by committed preadipo-
cytes. VSTM2A expression is elevated in the early
phases of adipogenesis in vitro and adipose tissue
development in vivo. We show that VSTM2A-pro-
ducing cells associate with the vasculature and
express the common surface markers of adipo-
cyte progenitors. Overexpression of VSTM2A in-
duces adipogenesis, whereas its depletion impairs
this process. VSTM2A controls preadipocyte deter-
mination at least in part by modulating BMP
signaling and PPARg2 activation. We propose a
model in which VSTM2A is produced to preserve
and amplify the adipogenic capability of adipose
precursors.
INTRODUCTION
White adipose tissue (WAT) is the primary site for energy storage
in mammals. This tissue stores triglycerides in periods of energy
excess and releases fatty acids to provide energy during fasting.
Beyond its role in controlling energy homeostasis, WAT serves
as a central endocrine organ playing key roles in metabolism.
WAT secretes a plethora of proteins termed adipokines that
have profound effects on various biological processes including
the regulation of food intake, glucose metabolism, insulin sensi-
tivity, inflammation, and reproduction (Rosen and Spiegelman,
2014). Compared to WAT, brown adipose tissue (BAT) is
specialized for thermogenic energy expenditure. In response
to cold, BAT hydrolyses triglycerides and oxidizes fatty acids
and glucose to produce heat (Cannon and Nedergaard, 2004).
Owing to its significant capacity to dissipate energy and regu-
late metabolism, this tissue is envisioned as a potential target
for the treatment of obesity and diabetes (Cypess and Kahn,
2010).
Studies in mice indicate that, during development, white and
brown adipose precursors actively proliferate before turning on
the expression of genes required for the development, the matu-
ration and the maintenance of mature adipocytes (Hong et al.,
2015; Hudak et al., 2014; Schulz et al., 2013; Tang et al.,
2008). Reports have shown that the timing of proliferation versus
hypertrophy differs between developing adipose depots (Hudak
et al., 2014; Wang et al., 2013). Whereas subcutaneous
WAT (sWAT) progenitors proliferate in utero and start to expand
through hypertrophy at birth, these events occur postnatally
in visceral epididymal WAT (eWAT) (Han et al., 2011; Hudak
et al., 2014; Wang et al., 2013). In the case of BAT, adipose
progenitors actively proliferate during late gestational stages
(Schulz et al., 2013). The expansion of WAT observed in
response to obesity also follows a tissue-specific pattern. In
response to a high-fat diet, sWAT grows primarily through adipo-
cyte hypertrophy (Jeffery et al., 2015; Wang et al., 2013). On the
other hand, eWAT rapidly expands via de novo adipogenesis and
hypertrophy of existing adipocytes (Jeffery et al., 2015; Wang
et al., 2013).
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While there has been significant advance in the under-
standing of the molecular mechanisms regulating the terminal
differentiation of adipocytes, the identity of adipocyte pre-
cursors and the events that regulate their adipogenic con-
version is only emerging (Berry et al., 2013, 2014; Cawthorn
et al., 2012). Early work have shown that white adipocytes
develop from a structure originally described as the ‘‘primitive
organ,’’ a cluster of blood vessels found during the develop-
ment of diverse organisms, including mice and humans
(Wassermann, 1965). The close association between vascu-
lature and adipogenesis has since been demonstrated
several times (Han et al., 2011; Nishimura et al., 2007; Rup-
nick et al., 2002; Tang et al., 2008). Recently, cell-surface
markers were used to isolate and characterize adipose
precursor from WAT. This led to the identification of
Lin–, CD29+, CD34+, Sca+, CD24+ as adipose progenitors
capable to differentiate and reconstitute WAT in vivo (Rode-
heffer et al., 2008). Adipose precursors were also shown to
express high levels of preadipocyte factor-1 (Pref-1) (Hudak
et al., 2014), peroxisome proliferator-activated receptor g2
(Pparg2) (Tang et al., 2008), and/or zinc-finger protein 423
(Zfp423) (Gupta et al., 2010, 2012) at various stage of their
development.
Despite progress in our comprehension of mechanism regu-
lating adipocyte development and expansion, the nature of the
factors that functionally characterize adipose precursors is still
elusive. Here, we report the discovery of V-set and transmem-
brane domain containing 2A (VSTM2A) as a protein highly
expressed and secreted by committed preadipocytes. VSTM2A
is expressed early during adipocyte development in vitro
but also during adipose tissue formation in mice and hu-
mans. Anatomical analyses of developing WAT revealed that
VSTM2A-producing cells closely associate with the vasculature
and that VSTM2A expression is enriched in adipose precursor
cells compared to mature adipocytes. We find that VSTM2A
is sufficient to induce spontaneous differentiation, whereas
its depletion impairs adipogenesis. Here, we show that
VSTM2A controls preadipocyte determination at least in part
by modulating bone morphogenetic protein (BMP) signaling
and PPARg2 activation. Our results indicate that VSTM2A is
an adipogenic regulator that promotes the commitment of
preadipocytes.
RESULTS
Identification of VSTM2A as a Factor Expressed by
Committed Preadipocytes
As reported by Green et al. in 1974, the potential for adipogene-
sis greatly varies within a culture of 3T3-L1 cells (Green and
Meuth, 1974), an in vitromodel of adipogenesis. Following the in-
duction of adipogenesis, some cells accumulate a large amount
of lipids, whereas others are unable to do so (Figure 1A). To iden-
tify new genes that functionally characterize committed preadi-
pocytes, we have set up a simple approach using these cells,
as described previously (Gupta et al., 2010). A schematic view
of the strategy is presented in Figure S1A. Briefly, we performed
limiting dilutions of a 3T3-L1 culture and successfully derived
new clonal sub-lines of 3T3-L1. Strikingly, when stimulated
with an adipogenic cocktail, these clones showed either a low,
mid, or high capacity to accumulate lipids (Figures 1B, 1C,
S1B, and S1C). The adipogenic capability of each line wasmain-
tained after several passages, indicating a persistent phenotype.
qRT-PCR analyses revealed that the low lines showed a lower
expression of key adipogenic and lipogenic genes over the
course of adipogenesis (Figure S1D). Importantly, the reduced
adipogenic potential of the low lines was corrected by treating
the cells with a PPARg agonist, indicating that despite their
inability to differentiate under normal conditions, these cells re-
tained the full potential to become mature adipocytes (Figures
S1E–S1G).
Being interested in identifying factors characterizing preadipo-
cytes, we used proliferating low and high lines and looked
at the expression of key adipogenic regulators. Consistent with
recent reports showing that Pparg2 is a key marker enriched
in preadipocytes (Gupta et al., 2010; Tang et al., 2008), we
observed that high lines expressed higher basal levels of Pparg2
(Figure 1D). Pparg1 was also slightly elevated in these cells.
Interestingly, the elevated basal Pparg1 and 2 levels were not
associated with major changes in the expression of many factors
known to regulate their own expression (Figure S1H). Of note, we
did not observe a significant difference in Zfp423 expression be-
tween the lines, indicating that basal Pparg2 expression can be
regulated independent of, or in parallel with this factor recently
shown to play key roles in regulating preadipocyte determination
(Figure S1H) (Gupta et al., 2010). To better characterize the tran-
scriptional signature defining the adipogenic potential of the low
and high lines, we performed a microarray analysis of these cells
still in the sub-confluent state. We observed that the expression
profiles of the high lines clustered together and significantly
differed from the ones of the low lines (Figure S1I; Table S1).
Several genes known to participate in the adipogenic process
were enriched in the high lines, including Pparg, Ap2, Cd36,
and Plin4 (Figure 1E). We found that the most differentially ex-
pressed gene between the high and low lines was a gene with
unknown function, V-set and transmembrane domain containing
2A (Vstm2a) (Figure 1E). qRT-PCR and western blotting analyses
confirmed that VSTM2A is highly expressed in cells with a high
adipogenic potential (Figures 1F and 1G). Altogether, these
results identify VSTM2A as a factor expressed by committed
preadipocytes in vitro.
In the studies described above, we noted a positive correlation
between Vstm2a and Pparg2 mRNA expression (Figure S1J).
Interestingly, forcing the adipogenic commitment of NIH 3T3
fibroblasts through the overexpression of PPARg2 was sufficient
to increase Vstm2a expression in sub-confluent cells, prior to
their differentiation (Figures S1K and S1L). A similar increase
in Vstm2a expression was measured in response to PPARg2
overexpression in other preadipocyte models including 3T3-L1
and C3H10T1/2 (Figures S1M and S1N). To better define the
relation between PPARg2 and Vstm2a expression, we have
overexpressed PPARg2 in immortalized cancer cell lines (293T
and U87). Because these cells cannot commit to the adipogenic
lineage and differentiate into adipocytes, they represent a
good model to define whether PPARg2 directly controls Vstm2a
expression or indirectly controls its expression by promoting adi-
pogenic commitment. As expected, overexpression of PPARg2
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strongly increased the expression Ap2 a well-established direct
target of PPARg2 (Figures S1O and S1P). However, PPARg2
completely failed in inducing the expression of Vstm2a in cancer
cells (Figures S1O and S1P). These results confirm that adipo-
genic commitment, downstream of PPARg2, is a strong driver
of Vstm2a expression in preadipocytes.
VSTM2A Is a Conserved Protein Expressed Early during
Adipocyte Development
VSTM2A is a 236 amino acid protein that carries a signal peptide
in the N-terminal and an immunoglobulin v-set domain in its
central section (Figure 2A). This protein is highly conserved
throughout evolution with homologs being found from human
to zebrafish (Figure S2A). Because available data on VSTM2A
are very limited, we first looked at its expression during adipo-
cyte differentiation in vitro. As shown in Figures 2B and 2C, the
induction of adipogenesis in 3T3-L1 cells was associated with
a transient increase in the expression of VSTM2A. Notably, the
induction in VSTM2A levels preceded the elevation in PPARg
and Ap2 expression. These effects were also observed when
adipogenesis was induced in other cellular models including
mouse embryonic fibroblasts (MEFs), WAT-derived stromal
vascular fraction (SVF), C3H10T1/2 mesenchymal stem cells
(MSCs), and human primary MSCs (Figures S2B–S2E). A very
similar profile was also observed during the differentiation of
immortalized brown preadipocytes (Figure S2F). These observa-
tions indicate that VSTM2A is expressed early during fat cell for-
mation in vitro and implicate a role for this protein in regulating
the early stages of adipocyte development. These results also
show that the positive relation between Pparg2 and Vstm2a
reported in proliferating preadipocytes (Figures S1J and S1L–
S1N) is lost in terminally differentiated cells and further support
the idea that Vstm2a is not a direct target of PPARg2.
We next looked at VSTM2A expression in mouse tissues, aim-
ing to find a distribution pattern that may reflect a role for the pro-
tein in adipose tissue biology. Our first survey of adult mice
showed that VSTM2A expression was essentially restricted
to the central nervous system and neurons (Figures 2D and
S2G and S2H). Because we identified VSTM2A as a factor highly
expressed in preadipocytes and in developing fat cells, we
reasoned that its expression might be enriched in the early
phases of adipose tissue formation. In mice, eWAT develops
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Figure 1. Identification of VSTM2A as a Gene Highly Expressed in Committed Preadipocytes
(A) Examples of 3T3-L1 showing either low or high adipogenic capacity. Cells were stained with DAPI (blue) and LipidTox red (red) to stain the nuclei and the lipid
droplets, respectively. Pictures of cells were taken from the same well 8 days following the induction of adipogenic differentiation.
(B) Triglyceride accumulation measured in 23 clonal lines of 3T3-L1 following the induction of differentiation. Lipid content was measured per well (n = 3/cell line)
8 days after the induction of differentiation. Data are presented as mean ± SEM. The difference between the low and high lines was confirmed in another in-
dependent experiment.
(C) Oil red O staining of low and high lines 8 days following the induction of differentiation. These pictures were produced from a single experiment.
(D) qRT-PCR analyses of Pparg2 and Pparg1 mRNA in subconfluent low (n = 7) and high (n = 8) cell lines. Data are presented as mean ± SEM and are repre-
sentative of two independent experiments. *p < 0.05 versus low lines.
(E) Heatmap showing the differential expression profile of several genes between low (n = 5) versus high (n = 5) linesmeasured bymicroarray. These data are from
a single experiment.
(F) qRT-PCR analyses of Vstm2a mRNA expression in subconfluent low (n = 7) and high (n = 8) cell lines. Data are presented as mean ± SEM and are repre-
sentative of two independent experiments. *p < 0.05 versus low lines.
(G) Western blot analysis of VSTM2A protein levels in low, high, and parental 3T3-L1 cells. S6Kwas used as a loading control. These images are representative of
at least three independent experiments.
See also Figure S1 and Table S1.
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postnatally, whereas sWAT develops in utero (Han et al., 2011;
Wang and Scherer, 2014). To determine whether VSTM2A is ex-
pressed in the developmental phase of adipose tissue, pups
were examined 4 days postnatal (P4), and VSTM2A levels were
measured in several tissues. Strikingly, we found that VSTM2A
was expressed in eWAT of P4 mice (Figure 2E). When the
expression of VSTM2A was analyzed in detail during eWAT
development (P4–P56), we observed that its expression was
critically high after birth but reduced as the tissue started to ex-
press more PPARg and to accumulate lipids (Figures 2F–2H). An
identical expression profile was observed when VSTM2A levels
were measured during the developmental phase of sWAT, i.e.,
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(A) Structure of human and mouse VSTM2A protein.
(B) qRT-PCR analyses of Vstm2a, Pparg2, and Ap2 mRNA expression in 3T3-L1 cells at sub-confluence (sub) or 0, 2, 4, and 8 days following the induction of
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(C) Western blot analysis of protein isolated from differentiating 3T3-L1 cells. These images are from a single western blot experiment. The data presented are
representative of two independent experiments.
(D) Western blot analysis showing the tissue distribution of VSTM2A in adult mouse (n.s., non-specific band). The image is representative of two experiments
performed with tissues collected from two other animals.
(E) Western blot analysis showing the tissue distribution of VSTM2A in a mouse sacrificed at postnatal day 4 (P4). The image is the representative of two ex-
periments performed with tissues collected from two different animals.
(F) Western blot analysis of VSTM2A protein levels in mice sacrificed at P4, P7, P14, P28, and P56. The image is representative of two additional independent
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(I) Western blot analysis of VSTM2A protein levels in WAT isolated from human fetuses at various stages of their development and in WAT isolated from adult
humans. This experiment was performed once.
See also Figure S2.
96 Cell Reports 18, 93–106, January 3, 2017
from E16.5 to P14 (Figure S2I), indicating that the early expres-
sion of VSTM2A is a phenomenon that is conserved between
WAT depots.
To test whether VSTM2A is also expressed in the develop-
mental phase ofWAT in humans, VSTM2A levels weremeasured
in sWAT collected from human fetuses. Light microscopy ana-
lyses of human fetuses previously showed that WAT appears
and progressively develops from the 14th to the 24th weeks of
gestation (Poissonnet et al., 1983, 1984). We observed that
VSTM2A was highly enriched in sWAT isolated from fetuses
but was not detected in adults (Figure 2I). Interestingly, VSTM2A
levels declined as the fetus developed, exactly as observed in
mice. Altogether, these results show that VSTM2A is expressed
early during adipocyte development in vitro and in vivo and that
this process is conserved from mice to humans.
VSTM2A-Expressing Cells Closely Associate with the
Vasculature in Developing WAT and Express Markers of
Adipose Progenitors in Adult WAT
Studies have reported that adipose progenitors closely asso-
ciate with the adipose vasculature and that these cells can pro-
liferate and differentiate into mature adipocytes (Jiang et al.,
2014; Tang et al., 2008). To determine whether VSTM2A-ex-
pressing cells show a similar distribution pattern, immunofluo-
rescence assays were performed on eWAT isolated from P4
mice. These experiments revealed that VSTM2A-expressing
cells are found exclusively in the perivascular compartment,
in close association with cells expressing the endothelial cell
marker CD31 (Figure 3A). As shown in Figure 3B, VSTM2A pos-
itive cells did not express alpha smooth muscle actin (aSMA), a
marker of mural cells. Importantly, we did not observe co-stain-
ing between VSTM2A, CD31, or aSMA, indicating that VSTM2A-
expressing cells are distinct from endothelial and mural cells. An
important question arising from these results is whether VSTM2A
expression also characterizes preadipocytes found in adult
WAT. As shown in Figure 2D, we observed limited VSTM2A pro-
tein expression by western blotting in adult WAT. However,
Vstm2a mRNA was detected in these samples using qRT-PCR,
a more sensitive detection method. Because VSTM2A is tran-
siently expressed by preadipocytes during in vitro adipogenesis
and WAT development, we reasoned that its low expression in
adult WAT may be a reflection of the low relative abundance of
this specific cell population in this tissue. To confirm the specific
expression of Vstm2a in adipose precursor cells, eWAT from
adult mice was digested with collagenase and sorted to isolate
both mature adipocytes and Lin–, CD29+, CD34+, Sca1+,
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See also Figure S3.
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PDGFRa+ adipose progenitors, as described (Berry and Rode-
heffer, 2013; Church et al., 2014; Rodeheffer et al., 2008) (Figures
3C and S3A). This experiment revealed that Vstm2a expression
was enriched in Lin–, CD29+, CD34+, Sca1+, PDGFRa+ cells
compared to mature fat cells (Figure 3D), thus supporting
the hypothesis that Vstm2a expression characterizes adipose
precursors in vivo.
The development of obesity is associated with de novo adipo-
genesis in mice (Kim et al., 2014;Wang et al., 2013). The increase
in adipogenesis observed in response to a high-fat diet occurs
mainly in eWAT (Jeffery et al., 2015; Wang et al., 2013). To test
the impact of obesity on Vstm2a expression, mice were fed a
high-fat diet for 4 weeks, a time at which a wave of adipogenesis
was reported to occur (Wang et al., 2013). As expected, this diet
was sufficient to increase WAT accumulation (Figure S3B). As
previously shown in Figure 2D, we found that Vstm2a expression
was low in eWAT of lean mice, which probably reflects its spe-
cific expression by a small population of adipose progenitors
within WAT. Interestingly, Vstm2a expression was significantly
induced in response to high-fat feeding (Figure 3E). To determine
whether elevated Vstm2a expression could also be observed in
response to obesity in other mousemodels, eWATwas collected
from genetically obese ob/ob and db/db mice. Supporting the
findings described above, we found greater expression of
Vstm2a in eWAT of these obese mouse models compared to
their lean littermates (Figures 3F and 3G). Altogether, these re-
sults indicate that Vstm2a expression is induced during WAT
expansion.
VSTM2A Is a Glycoprotein Secreted by Committed
Preadipocytes
The presence of a signal peptide in the N-terminal section of
VSTM2A suggests that the protein may be secreted. To directly
test this possibility, V5-tagged VSTM2A was overexpressed in
various cell lines and culture media was collected for western
blot and immunoprecipitation analyses (Figure S4A). VSTM2A
was rapidly detected in the culture media of overexpressing
cells, thus confirming that the protein is effectively secreted (Fig-
ures 4A, S4B, and S4C). We observed that blocking protein
transport with Brefeldin A or deleting the signal peptide on
VSTM2A completely abrogated VSTM2A secretion (Figures 4B
and S4D). As shown in Figures 4A and 4B, the secreted form
of VSTM2A migrated at a higher molecular weight compared to
VSTM2A found in cells. Interestingly, two conserved asparagine
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Figure 4. VSTM2A Is a Glycoprotein Secreted by Committed Preadipocytes
(A) Western blot analyses of cell lysates and culture media of 293T cells overexpressing V5-VSTM2A. Cells were plated the day before and culture medium was
changed at time 0. Cells were lysed and culture mediumwas collected at the indicated time. S6Kwas used as a loading control. The images are representative of
two independent experiments.
(B) Western blot analyses of cell lysates and culture media of 293T cells overexpressing V5-VSTM2A and treated or not with Brefeldin A (3 mg/mL). S6K was used
as a loading control. The images are representative of three independent experiments.
(C) Western blot analyses of cell lysates and culture media of 293T cells overexpressing V5-VSTM2A and treated or not with tunicamycin (1 mg/mL). Cells were
plated the day before and pre-treated with tunicamycin for 6 hr. S6K was used as a loading control. The images are representative of three independent
experiments.
(D) Western blots analyses showing that VSTM2A is a glycoprotein. Lysates and media isolated from 293T cells overexpressing V5-VSTM2A were treated with
PNGase F following manufacturer’s instructions (NEB, P0407) and analyzed by western blotting. S6K was used as a loading control. The images are repre-
sentative of two independent experiments.
(E) Western blot analyses of cell lysates and culture media of 293T cells overexpressing wild-type (WT) V5-VSTM2A or V5-VSTM2A with asparagine to glutamine
(N/Q) mutations of N35, N175, or N35+N175. S6K was used as a loading control. This experiment was performed once.
(F) Western blots analyses showing that VSTM2A dimerizes following its secretion. Media was isolated from 293T cells overexpressing V5-VSTM2A was kept on
ice or denaturated by heat and/or b-mercaptoethanol. This experiment was performed three times.
(G) Western blot analyses of cell culture media of NIH 3T3, a low adipogenic 3T3-L1 line (4H4) a high adipogenic 3T3-L1 line (4D2) and parental 3T3-L1 cells. Cells
were plated until confluence and then the culture medium was changed (time 0), collected over 3 days, and analyzed for endogenous VSTM2A. This experiment
was performed three times with the same outcome.
(H) Western blot analysis of cell lysate and culture media collected from eWAT explants. Samples of eWAT were collected from P4 mice and incubated in DMEM
10% for the indicated time.
See also Figure S4.
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residues (N35 and N175) potentially subjected to N-linked glyco-
sylation were identified in VSTM2A (Figure S4E). Supporting the
idea that VSTM2A is a secreted glycoprotein, the migration
pattern of VSTM2A was severely modified when cells were
treatedwith tunicamycin, an agent that blocks N-linked glycosyl-
ation (Figure 4C). A similar profile was seen when proteins were
de-glycosylated in vitro with PNGase F (Figure 4D). Additionally,
asparagine to glutamine (N/Q) mutations of N35 and N175,
which block glycosylation of these residues, not only modified
the migration profile of VSTM2A but also impaired its secretion
(Figure 4E). These results indicate that N-linked glycosylation is
required for the proper maturation and the secretion of VSTM2A.
In addition to the conserved asparagine found in VSTM2A, we
noted the presence of unpaired cysteine residues, which sug-
gests that VSTM2A could form dimers. Western blot analyses
revealed the presence of an 80-kDa band that was sensitive to
denaturation, indicating the presence of dimers in this prepara-
tion (Figure 4F).
To determine whether VSTM2A secretion is specific to
committed preadipocytes, we next measured the secretion of
the endogenous protein in non-adipogenic (NIH 3T3 and low
line) versus adipogenic cells (high line and 3T3-L1). Our experi-
ments showed that VSTM2A is secreted only by committed pre-
adipocytes (Figure 4G). In line with these results, we observed
that eWAT explants isolated from P4 mice also secreted high
levels of VSTM2A (Figure 4H). Overall, these results indicate
that VSTM2A is a glycoprotein produced and secreted by prea-
dipocytes in vitro and in vivo.
Overexpression of VSTM2A Induces the Spontaneous
Differentiation of Preadipocytes, Whereas Its Depletion
Severely Impairs This Process
In order to evaluate whether VSTM2A impacts on adipogenesis,
we have overexpressed the protein in preadipocytes (3T3-L1)
and immortalized MSCs (C3H10T1/2). We initially observed
that VSTM2A overexpression did not affect adipogenesis when
induced with the classical differentiation cocktail (data not
shown). Due to the fact that the differentiation cocktail was spe-
cifically designed to maximize and accelerate the adipogenic
conversion in vitro, a complete differentiation being obtained
6–8 days following the induction, we thought that its use might
have cover possible pro-adipogenic functions of VSTM2A. To
test this possibility, cells were grown to confluence and sponta-
neous adipogenesis, i.e., differentiation without stimulation, was
analyzed over 20 days. Strikingly, overexpression of VSTM2A
increased the spontaneous differentiation and lipid accumula-
tion in both 3T3-L1 and C3H10T1/2 cells (Figures 5A and 5B).
The elevation in adipogenesis was associated with a significant
increase in the expression of several adipogenic markers in
both cell lines (Figure 5C). Using primers to specifically measure
endogenous Vstm2a mRNA, we found that overexpression of
VSTM2A was sufficient to increase endogenous Vstm2a levels
in 3T3-L1 (Figure 5D). Interestingly, we also found that expres-
sion ofPparg2, but notPparg1, highly correlatedwith the expres-
sion of endogenous Vstm2a (Figure 5E), supporting the idea that
VSTM2A specifically affects Pparg2 expression.
To determine whether secreted or intracellular VSTM2A was
responsible for the induction of adipogenesis, we have per-
formed co-culture experiments using a trans-well system (Fig-
ure 5F). Although VSTM2A-producing cells showed a significant
increase in adipogenesis, control cells exposed to the condi-
tioned media did not show any pro-adipogenic phenotype (Fig-
ure 5G). Supporting these results, overexpression ofD-VSTM2A,
which lacks a signal peptide and cannot be secreted (Figures
S5A and S5B), was sufficient to induce adipogenesis in cells ex-
pressing this isoform (Figure 5H). Consistent with these findings,
we observed that adding escalating doses of purified VSTM2A to
the culture media did not induce Pparg2 expression and did not
promote spontaneous adipogenesis (Figures S5C and S5D).
Moreover, adding anti-VSTM2A antibodies to the culture media
to neutralize the effect of secreted VSTM2A did not reduce
adipogenesis in VSTM2A-producing cells (data not shown). All
these results confirm that intracellular, but not extracellular
VSTM2A, promotes adipogenic commitment in vitro.
We next sought to determine the impact of VSTM2A depletion
on adipogenesis. We first identified two short hairpin RNA
(shRNA) that efficiently knockdown VSTM2A (Figure S6A). Using
these hairpins, we observed that VSTM2A depletion severely
impaired adipogenesis, both in 3T3-L1 and C3H10T1/2 cells
(Figures 6A and 6B). As expected, this effect was associated
with an important reduction in the expression of adipogenic
and lipogenic genes post-differentiation (Figures 6C and 6D).
The impact of VSTM2A depletion on adipogenesis was not
associated with a consistent defect in mitotic clonal expansion,
a key step required for the optimal adipogenic conversion of
3T3-L1 preadipocytes (Figure S6B). Notably, we observed that
VSTM2A depletion also reduced the development of brown ad-
ipocytes in vitro (Figures S6C and S6D). A significant reduction
in the expression of uncoupling protein 1 (Ucp1), a key marker of
differentiated brown adipocytes, was measured in VSTM2A-
depleted cells (Figure S6E). These results indicate that VSTM2A
plays role in the development of white and brown fat cells
in vitro.
VSTM2A Controls Adipogenic Commitment by
Amplifying BMP Signaling and Pparg2 Expression
In agreement with the above findings, we observed that VSTM2A
knockdown reduced basal expression of Pparg2 in proliferating
preadipocytes prior to differentiation (Figure 7A). The opposite
phenotype was found in cells overexpressing either VSTM2A
or D-VSTM2A (Figure 7B). Together, these results confirm a pos-
itive role for VSTM2A in the control of basal Pparg2 expression
and preadipocyte determination. Interestingly, treating cells
with the PPARg agonist rosiglitazone significantly improved adi-
pogenesis in VSTM2A-depleted cells (Figures 7C–7E and S7A–
S7C), indicating that VSTM2A affects adipose cell development
at least in part by modulating PPARg activation. Because intra-
cellular VSTM2A does not localize to the nucleus (Figure S7D),
we reasoned that VSTM2A unlikely regulates Pparg2 expression
directly. Bone morphogenetic protein (BMP) signaling pathway
has been described as key signaling node regulating cell fate de-
cision and adipogenesis, in part through the phosphorylation of
SMADs and the promotion of PPARg activation (Bowers et al.,
2006; Gupta et al., 2010; Jin et al., 2006; Schulz et al., 2013;
Tang et al., 2004; Tseng et al., 2008). To evaluate whether
VSTM2A controls adipogenesis by affecting BMP signaling, we
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measured the phosphorylation of SMAD1/5/8 in response to
VSTM2A depletion or overexpression. Strikingly, we observed
an important reduction in basal SMAD1/5/8 phosphorylation in
3T3-L1 cells depleted from VSTM2A (Figure 7F). Moreover,
VSTM2A depletion impaired the normal response to recombi-
nant BMPs (Figure 7G). The same effect was observed when
VSTM2A was depleted in brown preadipocytes (Figures S7E
and S7F). Confirming the relation between VSTM2A and
BMP signaling, cells overexpressing VSTM2A showed elevated
SMAD1/5/8 phosphorylation (Figure 7H). Importantly, such
elevation in SMAD1/5/8 activation was not observed when
VSTM2A was overexpressed in non-adipogenic NIH 3T3 (Fig-
ures S7G and S7H), a cell type in which VSTM2A failed to pro-
mote Pparg2 expression and to induce adipogenesis (Figures
S7I and S7J). The same was observed when VSTM2A was ex-
pressed in non-adipogenic cancer cell lines (Figures S7K and
S7L). Together, these results indicate that the effect of VSTM2A
on BMP signaling and Pparg2 expression is context specific and
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Figure 5. VSTM2A Induces the Spontaneous Conversion of Preadipocytes and MSCs into Adipocytes
(A) Western blot analyses of cell lysates of 3T3-L1 and C3H10T1/2 cells overexpressing VSTM2A.
(B) Pictures of 3T3-L1 and C3H10T1/2 cells overexpressing VSTM2A. Cells overexpressing VSTM2A were plated and spontaneous differentiation was analyzed
over 20 days. Representative pictures are shown. This experiment was performed twice for 3T3-L1 and four times for C3H10T1/2, in each case with similar
outcomes. Scale bar, 100 mM.
(C) qRT-PCR analyses of adipogenic genes measured in 3T3-L1 and C3H10T1/2 cells overexpressing VSTM2A and treated as described in (B). Data are pre-
sented as mean ± SEM (n = 4/condition). This experiment was performed twice. *p < 0.05 versus control.
(D) qRT-PCR analyses of endogenous Vstm2a mRNA expression measured in 3T3-L1 cells overexpressing VSTM2A and treated as described in (B). Data are
presented as mean ± SEM (n = 4/condition). This experiment was performed once. *p < 0.05 versus control.
(E) Correlation between endogenous Vstm2a mRNA and Pparg2 or Pparg1 in 3T3-L1 following spontaneous differentiation.
(F) Schematic representation of the co-culture experiments performed in C3H10T1/2 cells.
(G) Co-culture experiments performed in C3H10T1/2 cells. The producer cells are expressing either MSCV or VSTM2A, whereas the recipients are the cells that
are exposed to the media. Spontaneous differentiation was assessed 24 days post-confluence. The number of differentiated cells was counted across wells and
results are presented as fold increase versus control. This experiment was reproduced three times with the same outcome. Data are presented as mean ± SEM
(n = 18 well/condition). *p < 0.05 versus control.
(H) Spontaneous differentiation was assessed 24 days post-confluence in C3H10T1/2 cells overexpressing native VSTM2A or D-VSTM2A. The number of
differentiated cells was counted across wells and results are presented as fold increase versus control. This experiment was reproduced three times with the
same outcome. Data are presented as mean ± SEM (n = 24 well/condition). *p < 0.05 versus control.
See also Figure S5.
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occurs only in cells with a certain degree of adipogenic
commitment.
To test whether VSTM2A amplifies the adipogenic commit-
ment of preadipocytes by controlling BMP signaling, we tried
to rescue the adipogenic defect of VSTM2A knockdown cells
with BMP4. Similarly to previous findings (Gupta et al., 2010),
we found that BMP4 treatment increased basal Pparg2 expres-
sion (Figure 7I). Furthermore, treating cells with BMP4 was
sufficient to correct Pparg2 expression in VSTM2A-depleted
cells (Figure 7I). We next induced differentiation and found that
BMP4 treatment improved adipogenesis in VSTM2A knockdown
cells (Figures 7J and 7K). This effect was associated with a sig-
nificant increase in the expression of adipogenic and lipogenic
genes post-differentiation (Figure 7L), confirming the importance
of BMP signaling in the pro-adipogenic effects of VSTM2A. We
next tried to determine whether blocking BMP signaling with
LDN-193189, a cell permeable small molecule inhibitor of BMP
type I receptors, was sufficient to reduce adipogenesis in cells
overexpressing VSTM2A. We found that LDN-193189 reduced
SMAD1/5/8 phosphorylation, Pparg2 expression and sponta-
neous adipogenesis in VSTM2A-overexpressing cells (Fig-
ures 7M–7P). Altogether, these results indicate that functional
BMP signaling is necessary to transduce the pro-adipogenic
effects of VSTM2A. We propose a model in which VSTM2A is
produced by preadipocyte to maintain and amplify the adipo-
genic capability of these cells (Figure 7Q).
DISCUSSION
Despite significant advances in our comprehension of the
mechanisms regulating the terminal differentiation of adipo-
cytes, the identity of adipose precursor cells and the mecha-
nisms regulating their recruitment are still not well characterized.
Here, we report the discovery of VSTM2A as a secreted protein
expressed by committed preadipocytes. Our results show that
VSTM2A is produced in the early phases of adipogenesis
in vitro and adipose tissue development in vivo. Micro-anatom-
ical analyses of developing WAT revealed that VSTM2A-
expressing cells associate with the vasculature, a common
characteristic of adipose progenitors. In adult mice, VSTM2A
expression is enriched in adipose precursor cells and its expres-
sion is increased in WAT of obese mice. Despite being actively
secreted, we found that intracellular VSTM2A is sufficient to
induce the spontaneous adipogenic differentiation of mesen-
chymal stem cells and preadipocytes. Conversely, depleting
VSTM2A in preadipocytes severely impairs adipogenesis. We
show that VSTM2A controls adipogenesis at least in part by
modulating BMP signaling and PPARg2 activation. Our results
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Figure 6. VSTM2A Knockdown Impairs Adipogenesis
(A and B) Oil red O staining and triglyceride accumulation following the differentiation of (A) 3T3-L1 or (B) C3H10T1/2 cells infected with control or Vstm2a shRNA.
Pictures were taken 6 days after the induction of adipogenesis and are representative of more than ten independent experiments for 3T3-L1 and two independent
experiments for C3H10T1/2. Scale bar, 40 mM. Lipid content was measured per well (n = 4/group) 6 days after the induction of differentiation. Data are presented
as mean ± SEM. *p < 0.05 versus sh_Ctrl.
(C and D) qRT-PCR analyses of adipogenic genes measured 6 days after the differentiation of (C) 3T3-L1 or (D) C3H10T1/2 cells infected with control or Vstm2a
shRNA. Data are presented as mean ± SEM (n = 4/condition). The results presented are representative of three independent experiments in the case of 3T3-L1
and one experiment in the case of C3H10T1/2. * p < 0.05 versus sh_Ctrl.
See also Figure S6.
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Figure 7. VSTM2A Controls Adipogenic Commitment by Amplifying BMP Signaling and Pparg2 Expression
(A) qRT-PCR analyses of Pparg1 and Pparg2 expression measured in sub-confluent 3T3-L1 cells infected with control or Vstm2a shRNA. Data are presented as
mean ± SEM (n = 4/condition). This experiment was performed once. *p < 0.05 versus sh_Ctrl.
(B) qRT-PCR analysis of Pparg2 expression measured in sub-confluent C3H10T1/2 cells overexpressing native VSTM2A or D-VSTM2A. Data are presented as
mean ± SEM (n = 4/condition). The results presented are representative of five independent experiments. *p < 0.05 versus Ctrl.
(C) Oil red O staining following the differentiation of 3T3-L1 cells infected with control or Vstm2a shRNA and treated or not with the PPARg agonist rosiglitazone
(5 mM). Pictures were taken 8 days after the induction of adipogenesis and are representative of three independent experiments. Scale bar, 40 mM.
(D) Triglyceride accumulation assessed in the experiment described in (C). Data are presented as mean ± SEM (n = 3/condition). This experiment was performed
three times. *p < 0.05 versus shCtrl; #p < 0.05 versus no rosiglitazone.
(E) qRT-PCR analyses of adipogenic genes assessed in the experiment described in (C). Data are presented as mean ± SEM (n = 4/condition). *p < 0.05 versus
shCtrl; #p < 0.05 versus no rosiglitazone.
(F) Western blot analyses of 3T3-L1 cells infected with control or Vstm2a shRNA. Cells were lysed in basal conditions. This experiment was performed four times
with similar outcome.
(G) Western blot analyses of 3T3-L1 cells infected with control or Vstm2a shRNA treated or not with escalating doses of BMP2 or BMP4. Cells were serum-
deprived for 3 hr and treated with BMP2 or BMP4 for 1 hr. This experiment was performed twice.
(H) Western blot analyses of 3T3-L1 and C3H10T1/2 cells overexpressing or not VSTM2A. Cells were lysed in basal conditions. These experiments were per-
formed at least with five times with similar outcome.
(I) qRT-PCR analysis of Pparg2 expression measured in proliferating 3T3-L1 cells treated or not with BMP4 for 38 hr. Data are presented as mean ± SEM (n = 4/
condition). This experiment was performed once. *p < 0.05 versus shCtrl; #p < 0.05 versus no BMP4.
(legend continued on next page)
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indicate that VSTM2A is an adipogenic regulator that promotes
the commitment of preadipocytes.
We have identified Vstm2a as themost differentially expressed
gene between high and low 3T3-L1 cell lines. We showed that
prior to differentiation, preadipocytes with a high adipogenic po-
tential expressed high basal levels of Vstm2a. In these studies, a
positive association was observed between Vstm2a and Pparg2,
a nuclear receptor that controls both the commitment and
the terminal differentiation of preadipocytes (Berry et al., 2013).
Supporting a close relation between these players, we found
that overexpression of PPARg2 in several cell types (NIH 3T3,
3T3-L1, C3H10T1/2) was sufficient to induce their adipogenic
commitment and to promote a robust increase in Vstm2a
expression. Although these observations suggest that PPARg2
lies upstream of Vstm2a, several evidence indicate that this inter-
action is not as straightforward. Indeed, we found that overex-
pression of VSTM2A was sufficient to increase basal Pparg2
expression before the induction of adipogenesis. Conversely,
VSTM2A knockdown reduced Pparg2 transcription in sub-
confluent preadipocytes. These results indicate that PPARg2
and VSTM2A reciprocally regulate their expression in a feedfor-
ward fashion. In details, we found that PPARg2 indirectly pro-
motes Vstm2a expression by amplifying adipogenic commit-
ment in preadipocytes. On the other hand, VSTM2A promotes
Pparg2 expression by activating BMP signaling. Importantly,
this feedforward loop did not take place in non-adipogenic cell
lines, indicating that adipogenic commitment is a prerequisite
to support the relation between PPARg2 and VSTM2A. Our find-
ings clearly show that preserving the integrity of the feed forward
loop between PPARg2 and VSTM2A is crucial to maintain and
amplify the adipogenic potential of preadipocytes.
It is important to point out that the positive association be-
tween Vstm2a and Pparg2 expression is observed only in the
early phases of adipogenesis. Indeed, we found that themassive
induction in PPARg2 that occurs in the late phases of adipogen-
esis was associated with a reduction, rather than an increase, in
the expression of Vstm2a. These results further support that
Vstm2a is not a direct target of PPARg2 and that VSTM2A
does not participate in the late activation of PPARg2 in terminally
differentiated cells. It was recently observed that the Pparg pro-
moter contains five highly conserved non-coding elements that
behave as enhancers to control Pparg expression at the earliest
stages of adipocyte determination (Chou et al., 2013). Interest-
ingly, these elements do not participate in the activation of Pparg
in mature adipocytes (Chou et al., 2013). Whether VSTM2A
regulates basal Pparg2 expression in preadipocytes by promot-
ing the transactivation of these specific sequences through
a SMAD1/5/8-dependent process is an interesting possibility
that warrants further investigation.
VSTM2A is a glycoprotein secreted by committed preadipo-
cytes in vitro and in vivo. Despite numerous attempts, we found
no role for secreted VSTM2A in the regulation of adipogenesis
in vitro. Of note, we showed that overexpression of D-VSTM2A,
which lacks a signal peptide and cannot be secreted, was effi-
cient in promoting adipogenesis. This observation univocally re-
vokes the role of secreted VSTM2A in regulating adipogenic
commitment in vitro. Although this finding is somewhat surpris-
ing, the identification of an intracellular function for a protein
secreted by preadipocytes is not unique. For example, Wnt1-
inducible signaling pathway protein 2 (WISP2) was recently iden-
tified as an adipokine controlling adipogenesis through intra and
extracellular mechanisms (Gr€unberg et al., 2014; Hammarstedt
et al., 2013). Here, we show that VSTM2A regulates adipogenic
commitment at least by modulating BMP signaling through an
unknown mechanism. At the moment, the functions of secreted
VSTM2A remain to be determined. Although secreted VSTM2A
did not regulate adipogenesis in vitro, we cannot exclude the
possibility that this factor may contribute to adipose tissue
formation, maintenance, or expansion in vivo by regulating
other, non-cell-autonomous processes. For example, secreted
VSTM2A could modulate angiogenesis or neurogenesis, which
are processes that must be coordinated with adipocyte develop-
ment to provide adequate blood supply and facilitate innervation
during the formation of adipose tissues.
VSTM2A is highly expressed in the brain. Vstm2awas recently
identified by others as one enigmatic gene highly produced in
mouse brain (Pandey et al., 2014). Similarly to VSTM2A, the
early regulator of preadipocyte determination ZFP423 is also ex-
pressed at high levels in the brain (Vishvanath et al., 2016; Gupta
et al., 2010). Loss of ZFP423 was shown to impair adipogenesis
but also to cause severe defects in brain formation (Alcaraz
et al., 2006; Cheng et al., 2007; Gupta et al., 2010; Warming
et al., 2006). Interestingly, genome-wide analysis of gene
expression during adipogenesis of mouse embryonic stem cells
revealed a clear link between early adipogenesis and neural
development (Billon et al., 2010). These observations indicate
(J) Oil red O staining following the differentiation of 3T3-L1 cells infected with control or Vstm2a shRNA and treated or not with BMP4 (50 ng/mL) from sub-
confluence to day 0. Pictures were taken 6 days after the induction of adipogenesis and are representative of two independent experiments. Scale bar, 40 mM.
(K) Triglyceride accumulation assessed in the experiment described in (J). Data are presented as mean ± SEM (n = 3/condition). This experiment was performed
once. *p < 0.05 versus shCtrl; #p < 0.05 versus no BMP4.
(L) RT-qPCR analyses assessed in the experiment described in (J). Data are presented as mean ± SEM (n = 3-4/condition). *p < 0.05 versus shCtrl; #p < 0.05
versus no BMP4.
(M) Western blot analyses of protein lysates isolated form C3H10T1/2 treated or not with LDN-193189 (0.1 mM) for 24 hr.
(N) Oil red O staining following the spontaneous differentiation C3H10T1/2 cells (20 days) overexpressing MSCV or VSTM2A and treated or not with LDN-193189
(0.1 mM) for the duration of the study. This experiment was performed twice with similar outcome. Scale bar, 60 mM.
(O) The number of differentiated cells was counted across wells for each conditions (n = 12 wells/condition). Data are presented asmean ± SEM. *p < 0.05 versus
control.
(P) RT-qPCR analysis of Pparg2 expression measured in the experiment described in (N). Data are presented asmean ± SEM (n = 4-5/condition). *p < 0.05 versus
Ctrl; #p < 0.05 versus no LDN.
(Q) Schematic overview of the model proposed.
See also Figure S7.
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that some regulatory pathways are likely playing dual roles in the
development of adipocytes and neurons. At the moment, the
roles of VSTM2A in neurons and brain development remain
uncharacterized.
In conclusion, we report the identification of VSTM2A as a fac-
tor modulating adipogenic commitment. We provide evidence
that VSTM2A expression is required to maintain and amplify
the adipogenic capacity of adipose precursor cells. These
findings extend the current understanding of the mechanisms
regulating preadipocyte development, which could eventually
contribute to the generation of new tools to control adipose
tissue size and function and improve metabolic health.
EXPERIMENTAL PROCEDURES
Animal Care
All experimental protocols were approved by the Animal Ethics Committee of
Universite´ Laval (CPAUL) and in accordancewith the guidelines of the Canadian
Council onAnimalCare. AllmicewereonaC57BL/6J backgroundandwerepur-
chased from the Jackson Laboratory. The animals were fed a high-fat diet (60%
kCal from fat, ResearchDiets,D12492) for 4weeks. Allmicewere sacrificed, and
tissues were collected at the same time of day. Obese mice (ob/ob and db/db)
and lean controls (12 weeks) were purchased from the Jackson Laboratory
and maintained on a chow diet for the duration of the studies.
Human Samples
The experimental protocols performed with human adipose tissue samples
were approved by the Research Ethics Committee of the Institut universitaire
de cardiologie et de pneumologie de Que´bec – Universite´ Laval (IUCPQ-UL).
Biological tissues were obtained from a Biobank approved by the Research
Ethics Committees of CHU Sainte-Justine and CSSS Jeanne-Mance. Subcu-
taneous adipose cells were collected from fetal tissues obtained in a context of
voluntary termination of pregnancy (gestation period 16–23 weeks) and in all
cases the participants have signed an informed consent. Adult subcutaneous
adipose tissue samples were collected from non-smoker men aged between
48 and 63 years old with a median body mass index of 25.4. Patients treated
with glitazones were excluded.
Tissue Distribution of VSTM2A
The tissue distribution of VSTM2A was performed on mouse tissues isolated
from either 12-week-oldmice or pups sacrificed 4 days postnatal (P4). To study
VSTM2Aexpression duringdevelopment, eWAT and sWATwere collected from
mice at embryonic day 16.5 (E16.5) or P1, P4, P7, P14, P28, and P56. Subcu-
taneous WAT was collected from the inguinal region, whereas eWAT was
collecteddirectly under the testis. Tissueswere either frozen forwesternblotting
or RT-qPCR analyses or put into PBS and stained 15min at 37Cwith LipidTOX
red neutral lipid stain (1:250) (Life Technologies H34476). Pictures were taken
using the Evos fluorescence microscopy system (Life Technologies).
Immunofluorescence
Epididymal WAT samples were collected from P4 mice and slowly frozen in
OCT before being cut at the Histology Core Laboratory of Universite´ Laval.
Slides were fixed with cold acetone, blocked, and stained overnight at 4C
in 5% normal donkey serum diluted in PBS. The following primary antibodies
were used for immunofluorescence: VSTM2A (Acris, AP54523PU-N, dilution
1:200), CD31 (BD Pharmingen, 553370, 1:200), and aSMA (Abcam, AB8211,
1:200). Following the incubation with the primary antibodies, slides were
washed and incubated with the corresponding secondary antibodies (donkey
anti-rabbit 568, Life Technologies, A10042 1:100; goat anti-rat 488, Life Tech-
nologies A11006, 1:100) for 45 min in the dark at room temperature. After PBS
washing, slides were stained with DAPI (Life Technologies, D3571, 1:10,000)
for 10 min and then mounted using Fluoromount G mounting media (Southern
Biotech) and imaged by confocal microscopy (Microscope LSM800, Zeiss
Axio Observer Z1). For Immunofluorescence assays performed on cells, cells
were plate the day before on poly-l-ornithine coated slides. The cells were next
fixed with PFA 4%, permeabilized during 1 min with Triton X-100 (0.05%) and
blocked 30 min with normal donkey serum. Slides were incubated for 1 hr with
V5 antibody (13202S, Cell Signaling Technology, dilution 1:400) and for 45 min
with secondary antibody (donkey anti-rabbit 568, Life Technologies, A10042
1:100). Slides were stained with DAPI mounted using Fluoromount Gmounting
media, as described above.
Cell Culture
All immortalized cell lines used (3T3-L1, C3H10T1/2, NIH 3T3) were obtained
from ATCC and cultured following the instructions of this provider. Human pri-
mary MSCs were also purchased from ATCC (PCS500011). These cells were
maintained in MSC basal medium (PCS500030) complemented with 3%MSC
growth kit low serum (PCS500040) and were used at P4. MEFs were derived
from embryos (E13.5) and the SVF was isolated from WAT by collagenase
digestion, as described previously (Laplante et al., 2006). MEFs and SVF
were used at passage 1 or 2. Immortalized brown preadipocytes were kindly
provided by Dr. Shingo Kajimura. The cells were isolated as described (Gal-
mozzi et al., 2014). For the isolation of 3T3-L1 clones, serial dilutions were per-
formed to allow the isolation of a single cell per well (96-well plate format). Each
well was visually inspected by microscopy to confirm the presence of a single
colony per well. Wells with more than one colony were excluded. The clones
were amplified and always maintained at sub-confluence. The following pro-
cedure was used for the induction of adipogenesis in 3T3-L1 cells. Sub-
confluent cells were maintained in DMEM with 10% fetal bovine serum
(FBS). Two days after reaching confluence, cells were exposed to an adipo-
genic cocktail containing insulin (830 nM), dexamethasone (1 mM), and 3-iso-
butyl-1-methylxanthine (IBMX) (500 mM). This corresponds to day 0 (D0). Two
days later (D2), the culture mediumwas changed for DMEM 10%FBS contain-
ing insulin (830 nM). The same procedure was followed to induce adipogenesis
in human primary MSCs, SVF, NIH 3T3, and C3H10T1/2 cells, except that the
adipogenic cocktail was supplemented with the PPARg agonist rosiglitazone
(5 mM). Immortalized brown preadipocytes (90% confluent) were induced to
differentiate using an adipogenic cocktail containing insulin (5 mg/mL), triiodo-
thyronine (T3) (1 nM), dexamethasone (2 mg/mL), and IBMX (500 mM). After
3 days, the media was changed and cells were maintained in DMEM 10%
FBS supplemented with T3 (1 nM). To measure spontaneous differentiation,
3T3-L1 or C3H10T1/2 cells were plated to confluence and maintained in
DMEM 10% FBS until day 20. Media was changed every 10 days. LDN-
193189 (Sigma, SML-0559) was used to test the impact of BMP signaling on
spontaneous adipogenesis.
Microarray Analyses
Whole-genome gene expression was performed using the Affymetrix
GeneChip Mouse Gene 1.0 ST Array. The RNA was labeled and hybridized
using a standard metrix protocol. The quality of arrays was judged using stan-
dard quality control parameters and all arrays passed the quality control filters.
Expression values were extracted using the Robust Multichip Average (RMA)
method (Irizarry et al., 2003) implemented in the oligo package in R (Carvalho
and Irizarry, 2010). The Significance Analysis of Microarrays (SAM) method
was used to identify probe sets differentially expressed between groups.
The false discovery rate (FDR) and the fold change threshold were set at 5%
and 1.5, respectively. All analyses were carried out with the R statistical
software v.3.2.3 and Bioconductor packages.
Statistical Analyses
Data are expressed as mean ± SEM. Comparison between two experimental
conditions were analyzed by Student’s unpaired t test. Two-way ANOVA was
used to compare more than two experimental conditions. All statistical tests
were performed using GraphPad Prism (v.6.0c), and p < 0.05 was considered
statistically significant.
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper
is NCBI GEO: GSE90580. (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE90580).
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